KLK3 and prostate cancer: PSA cleavage of the peptide component of G115 resulted in the release of a lipophilic Leu-12ADT (Figure 3), selectively killing prostate cancer cells in vitro and in vivo, with minimal systemic toxicity to the tumor bearing animals [55,57].